Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections.
Sławomir LetkiewiczMarzanna Łusiak-SzelachowskaRyszard MiędzybrodzkiMaciej ŻaczekBeata Weber-DąbrowskaAndrzej GórskiPublished in: Antibiotics (Basel, Switzerland) (2021)
Patients with chronic urinary and urogenital multidrug resistant bacterial infections received phage therapy (PT) using intravesical or intravesical and intravaginal phage administration. A single course of PT did not induce significant serum antibody responses against administered phage. Whilst the second cycle of PT caused a significant increase in antibody levels, they nevertheless remained quite low. These data combined with good therapy results achieved in some patients suggest that this mode of PT may be an efficient means of therapy for urogenital infections and a reliable model for a clinical trial of PT.
Keyphrases
- pseudomonas aeruginosa
- multidrug resistant
- clinical trial
- muscle invasive bladder cancer
- end stage renal disease
- peritoneal dialysis
- drug resistant
- prognostic factors
- acinetobacter baumannii
- stem cells
- randomized controlled trial
- electronic health record
- big data
- open label
- machine learning
- mesenchymal stem cells
- cell therapy
- phase ii
- deep learning